乌鸦传媒

The (ICER) said that while subcutaneous semaglutide (Wegovy) "is more effective, less burdensome, and more cost effective than liraglutide [Victoza]," it "does not meet typical cost-effectiveness thresholds at its current estimated net price."

The FDA approved a label update for , which treats chronic kidney disease associated with type 2 diabetes, to now include data from the phase III FIGARO-DKD and FIDELIO-DKD trials on kidney and cardiovascular outcomes, Bayer announced.

was not only cost-effective for the treatment of kids with mild uncomplicated diabetic ketoacidosis, but was also linked with faster recovery and reduced length of hospital stay versus standard-of-care intravenous insulin infusion. (JAMA Network Open)

Of nearly 1.2 million people with type 2 diabetes living in the U.S., the increased from 22% in 2006 to 29% in 2017. (Diabetologia)

Are the next frontier in infertility medicine? (Nature)

In a preclinical proof-of-concept study, Adocia's investigational helped regulate glycemic control after implantation in rats with diabetes, reaching normoglycemia without insulin or immunosuppression.

Astellas Pharma announced positive findings from the of fezolinetant, an investigational oral non-hormonal vasomotor symptom treatment, adding to the 12-week phase III SKYLIGHT-2 trial findings.

Exposure to phthalates was linked with in a cohort of Chinese girls with early onset of puberty. (Scientific Reports)

Comment